Compare CSAN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSAN | TVTX |
|---|---|---|
| Founded | 1936 | N/A |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.3B |
| IPO Year | 2008 | 2013 |
| Metric | CSAN | TVTX |
|---|---|---|
| Price | $2.89 | $58.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $4.75 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 2.7M | 2.2M |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $321.51 | $44.76 |
| Revenue Next Year | $3.57 | $35.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.52 | $14.36 |
| 52 Week High | $6.01 | $57.85 |
| Indicator | CSAN | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 78.50 |
| Support Level | $2.52 | $41.75 |
| Resistance Level | $4.37 | N/A |
| Average True Range (ATR) | 0.12 | 2.31 |
| MACD | 0.07 | 0.72 |
| Stochastic Oscillator | 98.81 | 99.86 |
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.